STOCKHOLM, June 12, 2024 /PRNewswire/ — SmartCella Holding AB (“SmartCella”) held its 2024 Annual General Meeting on June 10. The company welcomed investors to its state-of-the art clinical GMP manufacturing facility in Stockholm to learn more about the progress of SmartCella during the last 12 months. In addition, the investors met and interacted with the new board members who all hold unique life science industry and medical expertise. The newly appointed Board of Directors will play a pivotal role as SmartCella embarks on its next strategic development phase.
SmartCella is an innovative biotechnology company with a vision to combine novel delivery platforms, such as the FDA-declared Extroducer, with developing cutting-edge cell and mRNA therapies. The team consists of global scientists, innovators and visionaries dedicated to shape the future of targeted medicine through innovation and solid clinical data with the ambition of making targeted medicine a reality to many.
At the Annual General Meeting, Anna Martling (Professor of Surgery and Scientific Director Life Science at Karolinska Institutet), Claude Dartiguelongue (previously senior roles with Lonza, Thermo Fisher Scientific and Becton Dickinson and Company), and Regina Fritsche-Danielson (PhD in Cardiovascular Physiology/Pharmacology and Senior Vice President and Global Head of Research and Early Development, Cardiovascular, Renal and Metabolic Diseases at AstraZeneca) were appointed new members of the SmartCella Board of Directors. Magnus Tornling, Partner and Global Head of Equity Capital Markets at private equity firm EQT, and Christian Kinch, founder and Chairperson, were re-elected. Thomas von Koch declined re-election.
Christian Kinch, Chairperson of SmartCella comments: “We founded SmartCella in 2014 and have since invested in science, clinical data, team development, and infrastructure. As we advance on our strategic journey, our new board members will bring immense value with their diverse backgrounds in academia, science, and the commercial aspects of global MedTech and life science companies. It is a testament to our strength that we can attract such high-caliber individuals to the Board, whose skills complement SmartCella’s strong in-house team. I am excited and humbled by the potential of our collaboration and the impact SmartCella can have in addressing global health challenges, such as cardiovascular diseases and cancer. Our goal is to bring the magic behind medical science to transform lives, and I could not have a better Board of Directors to help achieve this vision.” He continues: “I would like to extend my appreciation to Thomas von Koch for his dedication and support over the past ten years. His philosophy of future-proofing companies has significantly contributed to SmartCella’s development. We look forward to continuing our collaboration with Thomas as an advisor and anchor investor.”
Niklas Prager, CEO of SmartCella, says: “With a track record of exceeding our strategic commitments, I am delighted to continue developing SmartCella and collaborating closely with all the Board members. The SmartCella Board now encompasses comprehensive expertise across all relevant domains, including equity capital markets, biotechnology, life sciences, MedTech, as well as medical, clinical, and research. I believe this breadth of knowledge is truly unique and essential to SmartCella. For us, a solid scientific foundation is crucial, and we rely on evidence-based science rather than speculative scenarios with limited substance. We are well-positioned to significantly disrupt disease treatment and make cutting-edge therapies safely accessible to a wide range of patients in a not too distant future.”
Contact
Nina Nornholm, Head of Corporate Communication +46 708 550 356 [email protected]
About SmartCella Holding AB
SmartCella, founded in 2014, is an innovative biotechnology company based in Stockholm, Sweden. SmartCella’s vision is to combine first-in-class delivery platforms with cutting-edge cell and mRNA therapies to unleash the full potential of targeted therapies. The company has three main business units, Smartwise, SmartCella Solutions and ProCella.
Smartwise
Smartwise has developed a first-in-class endovascular device, the Extroducer, that enables direct-to-tissue drug delivery. This technology addresses a significant unmet need in the field novel therapies, enabling targeted delivery of a wide range of modalities for solid tumor treatment and tissue repair. Using standard equipment and routine interventional radiology approaches, the Extroducer provides access to hard-to-reach tissues by safely penetrating the vessel wall and delivering payload directly to the target location. Smartwise received regulatory approval from the US FDA for the Extroducer in June 2022 and is now actively licensing out the technology globally.
SmartCella Solutions
SmartCella Solutions has developed novel mRNA therapies and cell-mediated delivery platforms enabling localized protein expression. The company is now actively engaging in partnering discussions for out-licensing, as well as developing its own proprietary therapies.
ProCella
ProCella has advanced capabilities in developing proprietary stem cell therapies as well as in-house cGMP manufacturing. The first therapy, a cardiac progenitor cell, has now been taken through GLP tox and is approaching a clinical phase 1 trial in heart failure. The company recently completed the construction of its clinical GMP manufacturing facility, which has been approved by the Swedish authorities (GMP) and cleared for production. This infrastructure along with the team’s technical expertise and capabilities will underpin the company’s growing pipeline going forward.
Read more www.smartcella.com
Follow SmartCella on LinkedIn
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
